SGLT2抑制剂通过Na+/H+交换体发挥心脏保护作用的研究进展

doi:10.3969/j.issn.1003-9198.2025.06.017

摘要/Abstract

摘要： 随着对钠-葡萄糖共转运蛋白2(SGLT2)抑制剂研究的深入和临床的获益,SGLT2抑制剂已逐步被写入心力衰竭的指南中,但其心脏保护的作用机制尚不完全明确。研究显示,Na⁺/H⁺交换体(NHE)在SGLT2抑制剂的心脏保护作用中发挥重要作用,同时NHE也是治疗心脏肥大、心肌缺血再灌注的重要干预靶点。本文就NHE对心血管的作用及其在SGLT2抑制剂心脏保护作用中的机制进行综述。

关键词: 钠-葡萄糖共转运蛋白2抑制剂, Na⁺/H⁺交换体, 心力衰竭

Abstract: As research on sodium-glucose cotransporter 2 (SGLT2) inhibitors deepens and clinical benefits become evident, SGLT2 inhibitors have been gradually included in guidelines for heart failure management, although their mechanisms of cardioprotective effect remain not fully understood. The Na⁺/H⁺ exchanger (NHE) plays a crucial role in the cardioprotective effects of SGLT2 inhibitors, and NHE has also become an important target for drug intervention in cardiac hypertrophy and myocardial ischemia-reperfusion. This article reviews the role of NHE in cardiovascular function and its mechanism in the cardioprotective effects of SGLT2 inhibitors.

Key words: sodium-glucose cotransporter 2, Na⁺/H⁺ exchanger, heart failure

中图分类号:

R541

张心路, 何慧薇. SGLT2抑制剂通过Na⁺/H⁺交换体发挥心脏保护作用的研究进展[J]. 实用老年医学, 2025, 39(6): 617-620.

ZHANG Xinlu, HE Huiwei. Research progress on the cardioprotective effect of SGLT2 inhibitors through Na⁺/H⁺ exchanger[J]. Practical Geriatrics, 2025, 39(6): 617-620.

参考文献

[1] 中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024,52(03):235-275.
[2] SAVARESE G, BECHER P M, LUND L H, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology[J]. Cardiovasc Res, 2023,118(17):3272-3287.
[3] 马丽媛, 王增武, 樊静, 等. 《中国心血管健康与疾病报告2022》要点解读[J]. 中国全科医学, 2023,26(32):3975-3994.[4] 葛均波, 霍勇, 杨杰孚, 等. 慢性心力衰竭“新四联”药物治疗临床决策路径专家共识[J]. 中国循环杂志, 2022,37(8):769-781.
[5] HEIDENREICH P A, BOZKURT B, AGUILAR D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines[J]. J Am Coll Cardiol, 2022, 79(17): e263-e421.
[6] ZINMAN B, WANNER C, LACHIN J M, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015,373(22):2117-2128.
[7] MCMURRAY J J V, SOLOMON S D, INZUCCHI S E, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019,381(21):1995-2008.
[8] SOLOMON S D, MCMURRAY J, CLAGGETT B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction[J]. N Engl J Med, 2022,387(12):1089-1098.
[9] COX Z L, COLLINS S P, HERNANDEZ G A, et al. Efficacy and safety of dapagliflozin in patients with acute heart failure[J]. J Am Coll Cardiol, 2024,83(14):1295-1306.
[10] FLIEGEL L. Structural and functional changes in the Na⁺/H⁺ exchanger isoform 1, induced by Erk1/2 phosphorylation[J]. Int J Mol Sci, 2019,20(10):2378.
[11] ORLOWSKI J, GRINSTEIN S. Na⁺/H⁺ exchangers[J]. Compr Physiol, 2011,1(4):2083-2100.
[12] LI T, TUO B. Pathophysiology of hepatic Na⁺/H⁺ exchange (Review)[J]. Exp Ther Med, 2020,20(2):1220-1229.
[13] LU M, JIA M, WANG Q, et al. The electrogenic sodium bicarbonate cotransporter and its roles in the myocardial ischemia-reperfusion induced cardiac diseases[J]. Life Sci, 2021,270:119153.
[14] PARKER M D, MYERS E J, SCHELLING J R. Na⁺-H⁺ exchanger-1 (NHE1) regulation in kidney proximal tubule[J]. Cell Mol Life Sci, 2015,72(11):2061-2074.
[15] LI X, KARKI P, LEI L, et al. Na⁺/H⁺ exchanger isoform 1 facilitates cardiomyocyte embryonic stem cell differentiation[J]. Am J Physiol Heart Circ Physiol, 2009,296(1):H159-H170.
[16] FLIEGEL L. Regulation of the Na⁺/H⁺ exchanger in the healthy and diseased myocardium[J]. Expert Opin Ther Targets, 2009,13(1):55-68.
[17] SHIMIZU I, MINAMINO T. Physiological and pathological cardiac hypertrophy[J]. J Mol Cell Cardiol, 2016,97:245-262.
[18] SULEIMAN M, ABDULRAHMAN N, YALCIN H, et al. The role of CD44, hyaluronan and NHE1 in cardiac remodeling[J]. Life Sci, 2018,209:197-201.
[19] MEDINA A J, PINILLA O A, PORTIANSKY E L, et al. Silencing of the Na⁺/H⁺ exchanger 1(NHE-1) prevents cardiac structural and functional remodeling induced by angiotensin Ⅱ[J]. Exp Mol Pathol, 2019,107:1-9.
[20] KAWASE H, BANDO Y K, NISHIMURA K, et al. A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis[J]. J Mol Cell Cardiol, 2016,98:37-47.
[21] BOZKURT B, AHMAD T, ALEXANDER K M, et al. Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America[J]. J Card Fail,2023,29(10):1412-1451.
[22] LAMBERT R, SRODULSKI S, PENG X, et al. Intracellular Na⁺ concentration ([Na⁺] i) is elevated in diabetic hearts due to enhanced Na⁺-glucose cotransport[J]. J Am Heart Assoc, 2015,4(9):e002183.
[23] BAARTSCHEER A, SCHUMACHER C A, WUST R C I, et al. Empagliflozin decreases myocardial cytoplasmic Na⁺ through inhibition of the cardiac Na⁺/H⁺ exchanger in rats and rabbits[J]. Diabetologia, 2017,60(3):568-573.
[24] UTHMAN L, BAARTSCHEER A, BLEIJLEVENS B, et al. Class effects of sglt2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na⁺/H⁺ exchanger, lowering of cytosolic Na⁺ and vasodilation[J]. Diabetologia, 2018,61(3):722-726.
[25] CHUNG Y J, PARK K C, TOKAR S, et al. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na⁺/H⁺ exchanger-1 or lower [Na⁺] i in the heart[J]. Cardiovasc Res, 2021,117(14):2794-2806.
[26] KIM I, CHO H J, LIM S, et al. Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction[J]. Exp Mol Med, 2023,55(6):1174-1181.
[27] XU Y, ZHANG C, JIANG K, et al. Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria[J]. Acta Pharm Sin B, 2023,13(4):1671-1685.
[28] TRUM M, RIECHEL J, SCHOLLMEIER E, et al. Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF[J]. Cardiovasc Res, 2024,120(9):999-1010.[29] MARTINEZ E C, PASSARIELLO C L, LI J, et al. RSK3: a regulator of pathological cardiac remodeling[J]. IUBMB Life, 2015,67(5):331-337.
[30] MAEKAWA N, ABE J, SHISHIDO T, et al. Inhibiting p90 ribosomal S6 kinase prevents (Na⁺)-H⁺ exchanger-mediated cardiac ischemia-reperfusion injury[J]. Circulation, 2006,113(21):2516-2523.
[31] CHEN S, OVERBERG K, GHOUSE Z, et al. Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition[J]. Biomed Pharmacother, 2024,174:116477.
[32] ZHOU H, WANG S, ZHU P, et al. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission[J]. Redox Biol, 2018,15:335-346.
[33] NAKAO M, SHIMIZU I, KATSUUMI G, et al. Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload[J]. Sci Rep, 2021,11(1):18384.
[34] UTHMAN L, HOMAYR A, JUNI R P, et al. Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor α-stimulated human coronary arterial endothelial cells[J]. Cell Physiol Biochem, 2019,53(5):865-886.
[35] GUO H, YU X, LIU Y, et al. Sglt2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant[J]. Sci Transl Med, 2023,15(680):eabp9952.
[36] UTHMAN L, LI X, BAARTSCHEER A, et al. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na⁺] _c/ROS-pathway in human endothelial cells[J]. Biomed Pharmacother, 2022,146:112515.
[37] CHUNG C C, LIN Y K, CHEN Y C, et al. Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis[J]. Cardiovasc Diabetol, 2023,22(1):27.